CRL — Charles River Laboratories International, Inc. stock price, charts and financials

QT78Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (NYSE: CRL) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
278.06
-3.61-1.28%
CRLQT78Charles River Laboratories International, Inc.·NYSE
278.06-1.28%
News
Down 1.3% — PGNY vs. CRL: Which Stock Is the Better Value Option? (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E-EPS (ttm)-4.85Insider Own1.51%Shs Outstand48.17MPerf Week-0.07%
Market Cap13.39BForward P/E21.84EPS next Y12.73Insider Trans-22.80%Shs Float47.62MPerf Month-4.12%
Enterprise Value16.23BPEG-EPS next Q2.96Inst Own-Short Float5.32%Perf Quarter50.30%
Income-239.00MP/S3.35EPS this Y333.38%Inst Trans-Short Ratio2.85Perf Half Y81.68%
Sales4.00BP/B4.71EPS next Y12.49%ROA-3.17%Short Interest2.54MPerf YTD39.39%
Book/sh59.09P/C69.76EPS next 5Y9.81%ROE-7.72%52W High303.29 -8.32%Perf Year82.07%
Cash/sh3.99P/FCF36.17EPS past 3/5Y-ROIC7.72%52W Low144.26 92.75%Perf 3Y36.57%
Dividend Est.-EV/EBITDA73.44Sales past 3/5Y0.33% 6.55%Gross Margin32.24%Volatility3.54% 2.91%Perf 5Y-36.95%
Dividend TTM-EV/Sales4.06EPS Y/Y TTM-2525.00%Oper. Margin12.35%ATR (14)9.21Perf 10Y240.97%
Dividend Ex-Date-Quick Ratio1.04Sales Y/Y TTM-1.26%Profit Margin-5.96%RSI (14)51.31Recom2.24
Dividend Gr. 3/5Y-Current Ratio1.35EPS Q/Q-3.21%SMA20-2.57%Beta1.39Target Price282.36
Payout0.00%Debt/Eq0.95Sales Q/Q-2.71%SMA505.52%Rel Volume1.61Prev Close281.67
Employees19,000LT Debt/Eq0.94EarningsNov 04SMA20035.69%Avg Volume919.82KPrice278.06
IPO DateJun 23, 2000Option/ShortYes / YesEPS/Sales Surpr.10.14% 2.75%Net Debt/EBITDA12.86Volume1,481,163Change-1.28%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-17-26ReiteratedArgus ResearchHold$250$330
Sep-11-26ReiteratedEvercore ISI GroupOutperform$220$320
Aug-10-26ReiteratedPiper Sandler$300
Aug-10-26ReiteratedMizuho SecuritiesNeutral$230$264
Aug-07-26ReiteratedMorgan StanleyOverweight$260$300
Aug-06-26ReiteratedRobert W. Baird$255$291
Aug-06-26ReiteratedRBC CapitalOutperform$215$282
Aug-06-26UpgradeJP MorganNeutralOverweight
Aug-05-26ReiteratedBarclaysOverweight$220$300
Jul-20-26DowngradeCLSAOutperformHold
Latest News· Times ET
Sep-18-26
Sep-17-26
Sep-16-26
Sep-15-26
Sep-14-26
Sep-11-26
Sep-09-26
Sep-08-26
Sep-04-26
Sep-01-26
Aug-30-26
Aug-27-26
Aug-25-26
Company

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/27/2025
FY 2024
12/28/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,9994,0154,050
Cost of Goods Sold Incl. D&A2,7102,7902,718
Gross Profit1,2891,2261,332
Selling, General and Administrative Excl. Other754743751
Research and Development
000
Other Operating Expense41-25353
Operating Income494508227
Interest Expense106107126
Unusual Expense
Non-Operating Income (Expense)-571-500-8
Net Income Before Taxes-184-10093
Income Taxes534368
Consolidated Net Income-239-14410
Net Income From Continuing Operations-236-14225
Net Income-239-14410
EPS (Recurring)-4.84-2.910.20
EPS (Basic, Before Extraordinaries)-4.84-2.910.20
EPS (Diluted)-4.85-2.910.20
EBITDA221411581
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio930.80
Price To Sales Ratio3.342.542.34
Gross Margin32.2330.5432.89
Operating Margin12.3512.655.60
Net Margin-5.98-3.590.25
Shares Outstanding485051
Market Capitalization13,34710,1839,494
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$321.53$271.80$222.07$172.35$122.62 Close Price0.00M6.43M12.87M19.30M25.73MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FOSTER JAMES CDirectorAug 25 '26Sale300.0033,56110,068,30031,596Aug 27
FOSTER JAMES CDirectorAug 25 '26Option Exercise199.4233,5616,692,84565,157Aug 27
Parisotto Shannon MCEVP, Disc & Safety AssessmentAug 19 '26Option Exercise194.122,039395,8116,846Aug 20
Parisotto Shannon MCEVP, Disc & Safety AssessmentAug 19 '26Sale294.122,039599,7114,807Aug 20
Andrews Nancy CDirectorAug 18 '26Sale285.24573163,4431,438Aug 20
Andrews Nancy CDirectorAug 18 '26Option Exercise164.3057394,1442,011Aug 20
Girshick BirgitChief Executive OfficerAug 11 '26Option Exercise179.666,5001,167,79042,513Aug 13
Girshick BirgitChief Executive OfficerAug 11 '26Sale279.906,5001,819,35036,013Aug 13
Parisotto Shannon MCEVP, Disc & Safety AssessmentAug 11 '26Option Exercise179.663,714667,2578,521Aug 13
Parisotto Shannon MCEVP, Disc & Safety AssessmentAug 11 '26Sale279.663,7141,038,6574,807Aug 13
FOSTER JAMES CDirectorAug 10 '26Option Exercise179.6628,7335,162,17160,329Aug 11
FOSTER JAMES CDirectorAug 10 '26Sale275.0028,7337,901,57531,596Aug 11
Knell Michael GunnarSVP, Finance and CAOAug 06 '26Sale260.386,6451,730,25111,852Aug 10
Knell Michael GunnarSVP, Finance and CAOAug 06 '26Option Exercise196.122,345459,91014,197Aug 10
Creamer Victoria LEVP & Chief People OfficerAug 06 '26Option Exercise179.664,179750,79934,230Aug 10
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.